One big reason why CNS drug development has foundered
30 January 2015
When you want to develop a drug for, say, cancer, there are some very objective measures--such as survival rate--that tell regulators just how effective it is compared to a standard drug or placebo. But in diseases involving the brain, like depression or even Parkinson's, scientists often have to settle for crude measures for assessing how patients perform or feel after treatment. And the wild card here is a placebo effect that can be very difficult to factor into studies and has been fingered for the death of multiple development programs.
Atlas Genetics completes $20m Series C fundraising
29 January 2015
Atlas Genetics Ltd (“Atlas” or the “Company”), the ultra-rapid ‘test and treat’ molecular diagnostics company, today announces the completion of a Series C financing, raising $20 million from a syndicate including existing investors and one new investor, RMI Partners. New investor, RMI Partners, is a global life sciences venture capital firm, the largest in Eastern Europe. Existing investors include Novartis Venture Funds, Consort Medical plc, Johnson & Johnson Innovation - JJDC, Inc., LSP, BB Biotech Ventures and South West Ventures Fund. This newly announced financing follows on from the previously announced Series B fundraising of $25 million.
Interested in biotech financing in the U.K.?
29 January 2015
You'd have to be deaf, dumb and blind to have overlooked the supercharged sense of optimism at JP Morgan a few weeks ago. There's more money pumping into the industry through venture funds, private equity, IPOs and follow-ons than ever before. And today's news that the first trio of U.S. biotech IPOs got off the ground--with one potential breakout in the group--signals that the good times aren't over yet.
Emerging Asian pharma markets poised to show solid growth in 2015: report
29 January 2015
The emerging pharmaceutical markets of Asia are expected, with a few exceptions, to grow this year and beyond, most providing attractive platforms for investments in the local industries, according to a series of analyses.
Med tech chalks up solid year of new device approvals in 2014
29 January 2015
Medical device approvals continued at a steady clip in 2014 despite mounting pressure from lawmakers to roll out a more stringent review process. The FDA granted approvals for 33 innovative devices in 2014, up 43% over the number it OK'ed the year before, according to EP Vantage. FierceMedicalDevicescovered device approvals from the first half of the year in an earlier report.
FDA slaps down another Indian plant, adding to the industry's woes
28 January 2015
The FDA has banned imports to the U.S. from another Indian drugmaker, adding to a substantial list of Indian companies whose drugs are now prohibited from being sold in the U.S. The agency has taken the step against a plant owned by generic drugmaker Ipca Laboratories, Reuters reports.
Novo will soon open plant in Russia
28 January 2015
The Russian ruble maybe in rubble, but the economic challenges will not deter Novo Nordisk ($NVO), which is finishing up a plant in Russia. Five years in the planning and nearly three in construction, execs say it is needed to fulfill the drugmaker's long-term goals there.
FDA to publish guidance on social media and clinical trial e-consent in 2015
27 January 2015
The FDA has released a list of almost 100 draft drug guidance documents it plans to introduce or update in 2015. The documents cover a range of biotech IT-related topics, including electronic informed consent in clinical trials, links to third-party sites in social media adverts and statistical approaches to showing biosimilarity.
Nanotechnology Markets in Healthcare & Medicine
27 January 2015
In the field of nanomedicine research, the US accounts for one-third of all publications and half of patent filings. A comparison between Europe as a whole and the US shows that while Europe is at the forefront of research, the US leads in the number of patent filings. The strong patenting activity of US scientists and companies indicates a more advanced commercialization status.
$4B VC shop lays out its vision for the future of digital health
27 January 2015
Anyone with a passing interest in tech startups is unlikely to be shocked by Silicon Valley VC Andreessen Horowitz listing digital health as one of its top 16 trends. But as one of the organizations with some power over how these trends play out, the reasoning behind Andreessen Horowitz's list makes for interesting reading.
06 September 2024
NovaMedica expands its line of products for the treatment of Alzheimer’s disease
22 August 2024
Children visited the NovaMedica Innotech pharmaceutical manufacturing facility
14 June 2024
87% of cancer patients give positive ratings for medical care quality
18 September 2024
The Russian market of fillers and biorevitalizers grew by 21% in the first half of 2024
18 September 2024
Pharma’s Patient Reach Problem: Billions Still Left Behind
17 September 2024
17 September 2024